Friday, May 20, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Old FDA-approved drug may protect against lung injury and blood clots in severe COVID-19

by Medical Finance
in Coronavirus
Old FDA-approved drug may protect against lung injury and blood clots in severe COVID-19
10
SHARES
107
VIEWS
Share on FacebookShare on Twitter

An FDA-approved drug that has been in clinical use for more than 70 years may protect against lung injury and the risk of blood clots in severe COVID-19 and other disorders that cause immune-mediated damage to the lungs, according to a preclinical study from researchers at Weill Cornell Medicine and Cold Spring Harbor Laboratory.

The researchers, whose report appears Feb. 8 in JCI Insight, found that the drug disulfiram protected rodents from immune-mediated lung injury in two separate models of this type of injury: infection with the SARS-CoV-2 coronavirus that causes COVID-19, and a lung failure syndrome called TRALI that in rare cases occurs after blood transfusion.

“As we learn more about the underlying biology of these lung injuries, we may be able to specifically target the processes that are damaging the lung tissue,” said senior co-author Dr. Robert Schwartz, an associate professor of medicine in the Division of Gastroenterology and Hepatology at Weill Cornell Medicine and a hepatologist at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

Both types of lung injury are now known to be driven in part by immune cells’ formation of web-like structures called neutrophil extracellular traps, or NETs. These can trap and kill infectious organisms, but can also be harmful to lung tissue and blood vessels, causing the accumulation of fluid in the lungs (edema) and promoting the development of blood clots. Disulfiram blocks one of the steps in NETs formation.

The study was a collaboration between Dr. Schwartz’s research group and a group led by Dr. Mikala Egeblad, professor and cancer center co-leader at Cold Spring Harbor Laboratory.

Serendipity has attached to disulfiram almost from the start of its history as a medicine. The compound was originally used in the production of rubber, and was later investigated as an anti-parasite treatment. Incidental observations that people taking it became mildly sick whenever they drank alcohol led to its FDA approval in 1951 as a deterrent to alcohol consumption for people with alcohol use disorder.

Scientists found in 2020 that disulfiram also inhibits part of the inflammatory process that can lead to NET formation by white blood cells called neutrophils. The finding prompted the testing of disulfiram as a NET blocker. “NETs will damage the tissue, but since disulfiram interferes with gasdermin D, a molecule needed to produce NETs, no NETs are formed after disulfiram treatment,” Dr. Egeblad said.

After confirming in lab-dish experiments that disulfiram does greatly reduce the formation of NETs by human and mouse neutrophils, the researchers tested it in models of TRALI and COVID-19, two diseases that are known to feature extensive neutrophil invasion of the lungs, NET formation and often fatal lung damage.

In a mouse model of TRALI, disulfiram treatment a day before and then again three hours before induction of the syndrome allowed 95 percent of the animals to survive, compared to just 40 percent of those not treated with the drug. The findings showed that disulfiram, apparently by reducing NET formation, blocked the progressive damage to lung tissue and vessels that occurred in untreated mice, and in so doing allowed lung function to stabilize and recover relatively quickly after initial damage. By contrast, an inhaled drug called DNase 1, which has been investigated as a potential TRALI treatment, had no significant effect in improving the mouse survival rate even when administered minutes before TRALI induction.

In earlier collaborative work published in the Journal of Experimental Medicine, autopsy results suggested that NETs were present in severe COVID-19 patients and raised a novel possibility.

Currently there aren’t any good treatment options for COVID-related lung injury, so disulfiram appears to be worth investigating further in this regard, particularly in severe COVID-19 patients.”


Dr. Robert Schwartz, senior co-author

Next the researchers tested disulfiram in a golden hamster model of COVID-19. This form of COVID-19 is less severe than what is seen in the worst human cases, but disulfiram treatment a day before or a day after infection with SARS-CoV-2 led to clearly favorable outcomes: less NET formation, less scar-like tissue formation (fibrosis) in the lungs, and gene activity changes suggesting a significant reduction in the harmful inflammatory response without impairment of antiviral immunity.

By comparison, the standard severe-COVID-19 treatment dexamethasone, an immune-suppressing steroid drug, did less to protect lung tissue from disease-related changes, and led to higher levels of SARS-CoV-2 in the lungs.

“Disulfiram’s strong inhibitory effect on NET formation and its improvement of disease outcomes in different rodent models highlight the potential for its use and for the future development of even better inhibitors of NET formation in a variety of diseases,” Dr. Schwartz said. Other researchers have begun small clinical trials of disulfiram in COVID-19 patients, although the results of those trials have not yet been published, he noted.

Source:

Journal reference:

Adrover, J.M., et al. (2022) Disulfiram inhibits neutrophil extracellular trap formation protecting rodents from acute lung injury and SARS-CoV-2 infection. JCI Insight. doi.org/10.1172/jci.insight.157342.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Comparison of Moderna Versus Pfizer-Biontech COVID-19 Vaccine Outcomes: A Target Trial Emulation Study In the U.S. Veterans Affairs Healthcare System. Image Credit: BaLL LunLa/Shutterstock

Comparing the Moderna and Pfizer-Biontech vaccines against SARS-CoV-2 infection

by Medical Finance
May 20, 2022
0

Several vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed to combat the ongoing coronavirus disease 2019...

Study: Temporary hold of mycophenolate boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients. Image Credit: PhotobyTawat/Shutterstock

Withdrawing steroid treatment found to boost SARS-CoV-2 vaccine-induced immunity in kidney transplant recipients

by Medical Finance
May 20, 2022
0

In a recent study posted to the medRxiv* pre-print server, a team of researchers investigated the impact of the fourth...

Study: A method for variant agnostic detection of SARS-CoV-2, rapid monitoring of circulating variants, detection of mutations of biological significance, and early detection of emergent variants such as Omicron. Image Credit: Lightspring/Shutterstock

New method for monitoring circulating SARS-CoV-2 variants and detecting new ones

by Medical Finance
May 20, 2022
0

After more than two years of the coronavirus disease (COVID-19) pandemic, there is still a constant threat of evolving strains...

Fire closes hospital and displaces staff as Colorado battles omicron

Is my cloth mask good enough? The 2022 edition

by Medical Finance
May 20, 2022
0

The highly transmissible omicron variant is sweeping the U.S., causing a huge spike in covid-19 cases and overwhelming many hospital...

Study: Egg-derived anti-SARS-CoV-2 immunoglobulin Y (IgY) with broad variant activity as intranasal prophylaxis against COVID-19: preclinical studies and randomized controlled phase 1 clinical trial. Image Credit: NIAID

An egg-derived SARS-CoV-2 vaccine and treatment for COVID-19 disease

by Medical Finance
May 20, 2022
0

Coronavirus disease 2019 (COVID-19), caused by the rapid outbreak of severe acute respiratory disease coronavirus-2 (SARS-CoV-2), has claimed more than...

Study: Engineering SARS-CoV-2 Neutralizing Antibodies for Increased Potency and Reduced Viral Escape. Image Credit: LuXiFeR Bowlo / Shutterstock.com

Engineering higher affinity SARS-CoV-2 antibodies

by Medical Finance
May 20, 2022
0

With the widespread and rapid transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the number of hospitalizations is...

Next Post
Study: SARS-CoV-2 Omicron symptomatic infections in previously infected or vaccinated South African healthcare workers. Image Credit: DisobeyArt/Shutterstock

Exploring omicron infection in COVID-19 vaccinated and convalescent South African healthcare workers

Researchers identify gene expression signatures linked to suicide risk

Research may lead to the development of effective fasting-based therapies

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Comparative complete scheme and booster effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infections with SARS-CoV-2 Omicron (BA.1) and Delta (B.1.617.2) variants. Image Credit: Studio Romantic/Shutterstock
    Exploring the comparative efficacy of booster vaccines against SARS-CoV-2 Omicron and Delta variants
  • Study: Host and microbiome features of secondary infections in lethal covid-19. Image Credit: MDGRPHCS/Shutterstock
    Lung microbiome alterations and secondary-infections in lethal COVID-19
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply